Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | PPARD | Q03181 | 1/20 | 0.50 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.50 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12920238 | 0.98 | GPR84 (0.61) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL4282439 | 0.98 | GPR84 (0.61) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL16794740 | 0.98 | GPR84 (0.61) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL6492260 | 0.93 | CA2 (0.50) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL16794748 | 0.93 | CA2 (0.50) | GPR84FFAR1MAPTLCKPPARD | |
| Malic Acid SCHEMBL28445109 | 0.88 | GPR84 (0.59) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL11881784 | 0.86 | GPR84 (0.60) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL3466467 | 0.84 | GPR84 (0.59) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL11505927 | 0.84 | GPR84 (0.55) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL26692183 | 0.84 | GPR84 (0.55) | GPR84FFAR1MAPTLCKPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3080285-B1 | PROCESSES TO PREPARE ELONGATED 2-KETOACIDS AND C6-C10 COMPOUNDS THEREFROM VIA GENETIC MODIFICATIONS TO MICROBIAL METABOLIC PATHWAYS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2022-07-27 | — | — | EP | claimed |
| US-20160355850-A1 | PROCESSES TO PREPARE ELONGATED 2-KETOACIDS AND C6-C10 COMPOUNDS THEREFROM VIA GENETIC MODIFICATIONS TO MICROBIAL METABOLIC PATHWAYS | DOW AGROSCIENCES LLC | 2016-12-08 | — | — | US | claimed |
| EP-3080285-A1 | PROCESSES TO PREPARE ELONGATED 2-KETOACIDS AND C6-C10 COMPOUNDS THEREFROM VIA GENETIC MODIFICATIONS TO MICROBIAL METABOLIC PATHWAYS | Dow Global Technologies LLC (US) | 2016-10-19 | — | — | EP | claimed |
| WO-2015089127-A1 | PROCESSES TO PREPARE ELONGATED 2-KETOACIDS AND C6-C10 COMPOUNDS THEREFROM VIA GENETIC MODIFICATIONS TO MICROBIAL METABOLIC PATHWAYS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2015-06-18 | — | — | WO | claimed |
| EP-3519579-B1 | PROCESSES TO PREPARE ELONGATED 2-KETOACIDS AND C-5-C10 COMPOUNDS THEREFROM VIA GENETIC MODIFICATIONS TO MICROBIAL METABOLIC PATHWAYS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-11-05 | — | — | EP | disclosed |
| CN-111201321-B | Genetically modified isopropyl malate isomerase enzyme complex and preparation of elongated 2-keto acids and C using same5-C10Method for preparing compounds | 陶氏环球技术有限责任公司 | 2024-07-12 | — | — | CN | disclosed |
| EP-3688175-B1 | GENETICALLY MODIFIED ISOPROPYLMALATE ISOMERASE ENZYME COMPLEXES AND PROCESSES TO PREPARE ELONGATED 2-KETOACIDS AND C5-C10 COMPOUNDS THEREWITH | DOW GLOBAL TECHNOLOGIES LLC (US) | 2024-03-13 | — | — | EP | disclosed |
| US-11898181-B2 | Genetically modified isopropylmalate isomerase enzyme complexes and processes to prepare elongated 2-ketoacids and C5-C10 compounds therewith | DOW GLOBAL TECHNOLOGIES LLC | 2024-02-13 | — | — | US | disclosed |
| EP-3080285-B1 | PROCESSES TO PREPARE ELONGATED 2-KETOACIDS AND C6-C10 COMPOUNDS THEREFROM VIA GENETIC MODIFICATIONS TO MICROBIAL METABOLIC PATHWAYS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2022-07-27 | — | — | EP | disclosed |
| US-20220098567-A1 | GENETICALLY MODIFIED ISOPROPYLMALATE ISOMERASE ENZYME COMPLEXES AND PROCESSES TO PREPARE ELONGATED 2-KETOACIDS AND C5-C10 COMPOUNDS THEREWITH | DOW GLOBAL TECHNOLOGIES LLC (US) | 2022-03-31 | — | — | US | disclosed |
| US-11236310-B2 | Process to prepare elongated 2-ketoacids and C-5-C10 compounds therefrom via genetic modifications to microbial metabolic pathways | DOW GLOBAL TECHNOLOGIES LLC (US) | 2022-02-01 | — | — | US | disclosed |
| US-11230705-B2 | Genetically modified isopropylmalate isomerase enzyme complexes and processes to prepare elongated 2-ketoacids and C5-C10 compounds therewith | DOW GLOBAL TECHNOLOGIES LLC (US) | 2022-01-25 | — | — | US | disclosed |
| WO-2018063424-A1 | PROCESSES TO PREPARE ELONGATED 2-KETOACIDS AND C-5-C10 COMPOUNDS THEREFROM VIA GENETIC MODIFICATIONS TO MICROBIAL METABOLIC PATHWAYS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2018-04-05 | — | — | WO | disclosed |
| US-20160355850-A1 | PROCESSES TO PREPARE ELONGATED 2-KETOACIDS AND C6-C10 COMPOUNDS THEREFROM VIA GENETIC MODIFICATIONS TO MICROBIAL METABOLIC PATHWAYS | DOW AGROSCIENCES LLC | 2016-12-08 | — | — | US | disclosed |
| EP-3080285-A1 | PROCESSES TO PREPARE ELONGATED 2-KETOACIDS AND C6-C10 COMPOUNDS THEREFROM VIA GENETIC MODIFICATIONS TO MICROBIAL METABOLIC PATHWAYS | Dow Global Technologies LLC (US) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015089127-A1 | PROCESSES TO PREPARE ELONGATED 2-KETOACIDS AND C6-C10 COMPOUNDS THEREFROM VIA GENETIC MODIFICATIONS TO MICROBIAL METABOLIC PATHWAYS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2015-06-18 | — | — | WO | disclosed |
| US-20030181388-A1 | Substituted 2-aminobenzamide caspase inhibitors and the use thereof | CYTOVIA, INC. | 2003-09-25 | — | — | US | disclosed |
| US-6620782-B1 | Substituted 2-aminobenzamide caspase inhibitors and the use thereof | CYTOVIA, INC. | 2003-09-16 | — | — | US | disclosed |
| US-6576628-B1 | Matrix metalloprotease inhibitors; arthritis, corneal ulcers, arteriosclerosis | ROCHE DIAGNOSTICS GMBH (DE) | 2003-06-10 | — | — | US | disclosed |
| CN-1276786-A | 3-aryl-succinamido-hydroxamic acids, method for producing said acids and medicaments contg. same | ROCHE DIAGNOSTICS GMBH (DE) | 2000-12-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181388-A1 | Substituted 2-aminobenzamide caspase inhibitors and the use thereof | CASP2, CASP1, CASP3 | GPR84 1797/4885FFAR1 627/4885MAPT 4563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.